The estimated Net Worth of Charles A Bancroft is at least $10.1 Million dollars as of 10 March 2020. Mr. Bancroft owns over 71,868 units of Kodiak Sciences Inc stock worth over $379,483 and over the last 15 years he sold KOD stock worth over $9,686,196. In addition, he makes $0 as Independent Director at Kodiak Sciences Inc.
Charles has made over 39 trades of the Kodiak Sciences Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 71,868 units of KOD stock worth $177,514 on 10 March 2020.
The largest trade he's ever made was exercising 121,014 units of Kodiak Sciences Inc stock on 3 March 2014 worth over $298,905. On average, Charles trades about 21,480 units every 69 days since 2010. As of 10 March 2020 he still owns at least 153,637 units of Kodiak Sciences Inc stock.
You can see the complete history of Mr. Bancroft stock trades at the bottom of the page.
Charles A. Bancroft serves as Independent Director of the Company. He recently retired from a successful career at Bristol Myers Squibb (BMS) where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held numerous roles of increasing responsibility. He served as Chief Financial Officer from 2010 to 2019 and was appointed Executive Vice President, Head of Integration and Strategy & Business Development in 2019. He received his bachelor's degree in accounting from Drexel University and his M.B.A. in finance from Temple University .
Charles Bancroft is 60, he's been the Independent Director of Kodiak Sciences Inc since 2020. There are 3 older and 9 younger executives at Kodiak Sciences Inc. The oldest executive at Kodiak Sciences Inc is Robert Profusek, 70, who is the Lead Independent Director.
Charles's mailing address filed with the SEC is 1200 PAGE MILL ROAD, , PALO ALTO, CA, 94304.
Over the last 6 years, insiders at Kodiak Sciences Inc have traded over $15,919,920 worth of Kodiak Sciences Inc stock and bought 10,439,459 units worth $472,964,631 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bros. Advisors Lp667, L.P.B..., and Victor Perlroth. On average, Kodiak Sciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $393,170. The most recent stock trade was executed by John A. Borgeson on 15 June 2024, trading 5,494 units of KOD stock currently worth $13,570.
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Kodiak Sciences Inc executives and other stock owners filed with the SEC include: